Cargando…

Postnatal corticosteroid exposure in very preterm infants: A French cohort study

Background: Postnatal corticosteroids (PC) are widely used in very preterm infants. International reports and national multicenter trials describe a marked variability across countries and inter-sites, in the use of PC. Few information is available on therapeutic indications and prescription charact...

Descripción completa

Detalles Bibliográficos
Autores principales: Iacobelli, Silvia, Allamèle-Moutama, Käliani, Lorrain, Simon, Gouyon, Béatrice, Gouyon, Jean-Bernard, Bonsante, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113548/
https://www.ncbi.nlm.nih.gov/pubmed/37089932
http://dx.doi.org/10.3389/fphar.2023.1170842
_version_ 1785027863388356608
author Iacobelli, Silvia
Allamèle-Moutama, Käliani
Lorrain, Simon
Gouyon, Béatrice
Gouyon, Jean-Bernard
Bonsante, Francesco
author_facet Iacobelli, Silvia
Allamèle-Moutama, Käliani
Lorrain, Simon
Gouyon, Béatrice
Gouyon, Jean-Bernard
Bonsante, Francesco
author_sort Iacobelli, Silvia
collection PubMed
description Background: Postnatal corticosteroids (PC) are widely used in very preterm infants. International reports and national multicenter trials describe a marked variability across countries and inter-sites, in the use of PC. Few information is available on therapeutic indications and prescription characteristics of PC. Aim: The main objective of this study was to describe the exposure to PC in a large cohort of preterm infants born at less than 32 weeks of gestation, according to the prescription data of 41 tertiary-care NICUs in France. Secondary objectives were to describe therapeutic indications, day of life (DOL) of the first exposure, route of administration, duration, cumulative dose for each drug, and differences in exposure rates across centers. Methods: We conducted a prospective observational cohort analysis from January 2017 to December 2021, in 41 French tertiary-care NICUs using the same computerized order-entry system. Results: In total, 13,913 infants [birth weight 1144.8 (±365.6) g] were included. Among them, 3633 (26.1%) were exposed to PC, 21.8% by systemic and 10.1% by inhaled route. Within the study population, 1,992 infants (14.3%) received the first corticosteroid treatment in the first week of life and 1641 (11.8%) after DOL 7. The more frequent indications were prevention and/or treatment of bronchopulmonary dysplasia, and arterial hypotension. Hydrocortisone was the more often prescribed molecule. For systemic PC the first exposure occurred in mean at DOL 9.4 (±13.5), mean duration of treatment was 10.3 (±14.3) days, and the cumulative dose (expressed as the equivalent dose of hydrocortisone) was in median [IQR] 9.0 [5.5–28.8] mg/kg. For inhaled PC, the first exposure occurred in mean at DOL 34.1 (±19.7), and mean duration of treatment 28.5 (±24.4) days. The exposure rate ranged from a minimum of 5% to a maximum of 56% among centers, and significantly increased over the study period (p < 0.0001). Conclusion: In this French cohort of very preterm infants, around one patient out to five was exposed to PC during hospital stay in the NICU. The exposure occurred early, starting from the first week of life. Exposure rate widely varied among centers. Pharmacoepidemiology studies are useful to increase knowledge on corticosteroid utilization patterns in preterm infants.
format Online
Article
Text
id pubmed-10113548
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101135482023-04-20 Postnatal corticosteroid exposure in very preterm infants: A French cohort study Iacobelli, Silvia Allamèle-Moutama, Käliani Lorrain, Simon Gouyon, Béatrice Gouyon, Jean-Bernard Bonsante, Francesco Front Pharmacol Pharmacology Background: Postnatal corticosteroids (PC) are widely used in very preterm infants. International reports and national multicenter trials describe a marked variability across countries and inter-sites, in the use of PC. Few information is available on therapeutic indications and prescription characteristics of PC. Aim: The main objective of this study was to describe the exposure to PC in a large cohort of preterm infants born at less than 32 weeks of gestation, according to the prescription data of 41 tertiary-care NICUs in France. Secondary objectives were to describe therapeutic indications, day of life (DOL) of the first exposure, route of administration, duration, cumulative dose for each drug, and differences in exposure rates across centers. Methods: We conducted a prospective observational cohort analysis from January 2017 to December 2021, in 41 French tertiary-care NICUs using the same computerized order-entry system. Results: In total, 13,913 infants [birth weight 1144.8 (±365.6) g] were included. Among them, 3633 (26.1%) were exposed to PC, 21.8% by systemic and 10.1% by inhaled route. Within the study population, 1,992 infants (14.3%) received the first corticosteroid treatment in the first week of life and 1641 (11.8%) after DOL 7. The more frequent indications were prevention and/or treatment of bronchopulmonary dysplasia, and arterial hypotension. Hydrocortisone was the more often prescribed molecule. For systemic PC the first exposure occurred in mean at DOL 9.4 (±13.5), mean duration of treatment was 10.3 (±14.3) days, and the cumulative dose (expressed as the equivalent dose of hydrocortisone) was in median [IQR] 9.0 [5.5–28.8] mg/kg. For inhaled PC, the first exposure occurred in mean at DOL 34.1 (±19.7), and mean duration of treatment 28.5 (±24.4) days. The exposure rate ranged from a minimum of 5% to a maximum of 56% among centers, and significantly increased over the study period (p < 0.0001). Conclusion: In this French cohort of very preterm infants, around one patient out to five was exposed to PC during hospital stay in the NICU. The exposure occurred early, starting from the first week of life. Exposure rate widely varied among centers. Pharmacoepidemiology studies are useful to increase knowledge on corticosteroid utilization patterns in preterm infants. Frontiers Media S.A. 2023-04-05 /pmc/articles/PMC10113548/ /pubmed/37089932 http://dx.doi.org/10.3389/fphar.2023.1170842 Text en Copyright © 2023 Iacobelli, Allamèle-Moutama, Lorrain, Gouyon, Gouyon, Bonsante and the Logipren Collaborative Working Group. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Iacobelli, Silvia
Allamèle-Moutama, Käliani
Lorrain, Simon
Gouyon, Béatrice
Gouyon, Jean-Bernard
Bonsante, Francesco
Postnatal corticosteroid exposure in very preterm infants: A French cohort study
title Postnatal corticosteroid exposure in very preterm infants: A French cohort study
title_full Postnatal corticosteroid exposure in very preterm infants: A French cohort study
title_fullStr Postnatal corticosteroid exposure in very preterm infants: A French cohort study
title_full_unstemmed Postnatal corticosteroid exposure in very preterm infants: A French cohort study
title_short Postnatal corticosteroid exposure in very preterm infants: A French cohort study
title_sort postnatal corticosteroid exposure in very preterm infants: a french cohort study
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113548/
https://www.ncbi.nlm.nih.gov/pubmed/37089932
http://dx.doi.org/10.3389/fphar.2023.1170842
work_keys_str_mv AT iacobellisilvia postnatalcorticosteroidexposureinverypreterminfantsafrenchcohortstudy
AT allamelemoutamakaliani postnatalcorticosteroidexposureinverypreterminfantsafrenchcohortstudy
AT lorrainsimon postnatalcorticosteroidexposureinverypreterminfantsafrenchcohortstudy
AT gouyonbeatrice postnatalcorticosteroidexposureinverypreterminfantsafrenchcohortstudy
AT gouyonjeanbernard postnatalcorticosteroidexposureinverypreterminfantsafrenchcohortstudy
AT bonsantefrancesco postnatalcorticosteroidexposureinverypreterminfantsafrenchcohortstudy
AT postnatalcorticosteroidexposureinverypreterminfantsafrenchcohortstudy